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Common mullein weed (Verbascum thapsus) has a large number of synonyms and old local “nick names” which connect the
plant with mycobacteria. A strong history of medicinal use has been uncovered for the treatment of tuberculosis, tubercular skin
disease, leprosy, and mycobacterial disease in animals. Here, we examine problems encountered in treating such diseases today, the
historical and scientiﬁc links between mullein and pathogenic bacteria, and the possibility that this common weed could harbour
the answer to beating one of the world’s biggest infectious killers.
1. Tuberculosis: ModernDay Scourge
It has killed ancient Egyptians and Iron Age British settlers
as well as John Keats, D. H. Lawrence, and Vivien Leigh.
Throughout history, it has left its mark on our ancestors as
“phthisis”, “consumption”, and the “white plague”. But far
from being a disease of the past, Tuberculosis (TB) is now
killing almost 5000 per day, or one person about every 20
seconds [1]. The World Health Organisation (WHO) has
declared a global emergency [2] and as antibiotic resistance
increases [3], the hunt for new treatments continues.
2. TreatingTuberculosis—PresentandFuture
Mycobacteria are notoriously tough micro-organisms. Their
intrinsic resistance to many antibiotics can be largely
attributed to the unique structure of the cell envelope,
which is rich in high molecular weight fatty acids and
peptidoglycan cross-linkage [6]. Permeability is mainly
restricted to lipophilic molecules [7] such as the anti-TB
agent Rifampicin. This envelope also seems to be a dynamic
structure—changing according to whether the bacterium is
growing or persisting in host tissues [8]. A combination
of antibiotics is therefore required to treat mycobacterial
infection.CurrentIrishrecommendationsarethatallnewTB
patients (including HIV positive) who have not previously
been treated with anti-TB drugs receive the internation-
ally accepted ﬁrst line treatment regimen outlined by the
WHO [9]. This includes initial treatment with Isoniazid,
Rifampicin, Pyrazinamide, and Ethambutol for two months,
followed by a four-month continuation phase of further
treatment with Isoniazid and Rifampicin. In the case of a
60kgadult,thisequatestooverhalfakilogramofantibiotics.
Monthly sputum samples are examined for the continued
presence and/or reappearance of tubercle bacilli—in this
case, treatment needs to be modiﬁed due to resistance and
may be extended to 9 months or longer. Extensively drug-
resistant TB (often incurable) ﬁrst emerged in 2006 [10]a n d
has now been reported in over 50 countries worldwide [1].
The WHO recently reported that in some areas of the world,
oneinfourpeoplewithTBbecomesillwithaformofthedis-
ease that can no longer be treated with standard drugs [11].
Three of the four ﬁrst-line antibiotics listed above
work by directly or indirectly aﬀecting the synthesis of
the mycobacterial cell wall and this remains an area of
pharmaceutical interest [12]. The three compounds which
are currently in phase II/III clinical development (namely
moxiﬂoxacin, PA824, and TMC207) elicit their activity
by the inhibition of enzymes involved in cell division,
respiration, and mycolic acid synthesis [13, 14]. While these
newdrugsweresyntheticallyengineered,naturalcompounds
are once again playing a bigger role in the ﬁght against TB.2 Evidence-Based Complementary and Alternative Medicine
Plant extracts have been shown to be capable of inhibition
comparabletothatofStreptomycin[15],haveshownactivity
against multidrug resistant TB [16], and have been shown to
improve the immune response to TB both in vitro and in
clinical trials [17, 18]. Pharmaceutical science is increasingly
beginning to realise that the “silver bullet” compounds we
are attempting to engineer may have been present in nature
all along.
3.NatureasaSource of MedicinalCompounds
Up to half of pharmaceutical agents prescribed today
contain at least one ingredient derived from plants [19]—
an indication that mainstream medicine has become more
receptive to the use of drugs derived from botanical sources.
Some of the more well-known medicines entrusted to us by
Mother Nature include the analgesics codeine, salicin and
morphine, the antimalarial artemisinin, the antihistamine
ephedrine, and the cardiac drug digoxin. In many cases,
history has given scientists clues as to which plants may
contain therapeutic compounds. Of the 119 plant-derived
pharmaceutical medicines recently examined by the WHO,
about 74 percent are used in modern medicine in ways
that correlate directly with their traditional uses as herbal
medicines by native cultures [20]. As a result, scientists
involved in the hunt for new anti-TB drugs are beginning
to look to the past for inspiration. The Global Alliance for
TB Drug Development (TB Alliance) recently announced
a partnership with the Institute of Microbiology of the
Chinese Academy of Sciences (IMCASs) to discover and
develop promising, novel, and antituberculosis agents from
natural sources [21]. The Chinese are by no means the only
nationality to use traditional herbal remedies, nor the only
nationality to record them. The scientiﬁc discipline known
as ethnopharmacology aims to use the knowledge assembled
by indigenous peoples worldwide regarding the plants they
have used as traditional remedies in their own areas [22, 23].
Ireland is a country with a well-documented history of
tubercular disease and leprosy [24]. To date, however, no
research has been carried out into Irish traditional remedies
f o rm y c o b a c t e r i a ld i s e a s e ss u c ha sT B .
Ireland has a relatively low number of native vascular
p l a n ts p e c i e s ,a t8 1 5[ 25]. During a review of those plants
most used in traditional Irish medicine, one repeatedly
showed links to TB and other diseases caused by mycobac-
teria. This plant is Verbascum thapsus, or common mullein.
4. IrishMulleinWeed—Notes from History
Mullein has grown wild throughout Ireland for centuries—
on walls, wasteland, quarries, and roadsides. It can grow to
heights of up to two metres, with a round woolly stem, broad
basal leaves, and yellow ﬂowers which bloom from June to
September (Figure 1(a)) [4, 26]. This physical description
explains many of the synonyms used for this plant. These
include Candlewick Plant, Torches, Our Lady’s Flannel,
Shepherd’s Staﬀ, and Beggar’s Stalk [27]. Census catalogues
of the Irish ﬂora, vice-county maps, and hectad maps all
show the widespread distribution of mullein in Ireland [5,
28](Figure 1(b)).UponreviewingIrishtraditionalmedicine,
mullein soon becomes apparent as a leading remedy in
the treatment of tuberculosis. Even up until the relatively
recent introduction of antimycobacterial drugs, mullein was
cultivatedonalargescaleinthiscountryandevensoldinthe
capital’s best chemist shops [29]. A simple “pharmaceutical
trial” in the late nineteenth century showed that the herb
was beneﬁcial in cases of tuberculosis. Dr. Quinlan of St.
Vincent’s hospital (Dublin, Ireland) noted mullein as “a
trusted popular remedy in Ireland” and reported positive
ﬁndings in 6 out of 7 cases where the herb was used to treat
tubercular patients [30].
The ﬁrst English language herbals—written as far back
as the sixteenth century—also point to mullein as a TB
remedy and praise it’s soothing and expectorant properties.
Culpeper advises that mullein will help a persistent cough,
tumours, or inﬂammations of the throat [31], while Gerard
noted antibacterial properties of the plant, commenting on
its use as a food preservative [32]. In more recent times,
the extensive herbal collection by Grieve names mullein as
a “remedy of the greatest antiquity for coughs....cultivated
in gardens for the purpose.... in steady demand by suﬀerers
from pulmonary consumption” and notes that it “controls
the hacking cough of consumption....and bleeding of the
lungs” [27]. The ﬁne hairs which cover the surface of the
mullein leaf (Figure 1(c)) may themselves have encouraged
expectoration from the lungs, however, most traditional
remedies encourage straining the leaf decoction to remove
these before drinking [27]. The herb’s potential was also
noted across the Atlantic. King’s American Dispensatory
records that it is useful in cases of “protracted cough and
haemoptysis” [33] while the herbalist Edward Shook went so
far as to say that TB could be cured in its early stages using
this herb alone [34].
While its historical ties with tuberculosis abound, per-
haps even more intriguing is the mullein weed’s apparent
association with the genus Mycobacterium in general. While
revising historical remedies, we must consider our modern
day understanding of microbiology. It is now possible to
provethatdiseaseswhichwereoncebelievedtobecompletely
unrelated are in fact caused by the same pathogen. Mycobac-
teria are an example of this—causing a variety of infections
in humans and animals (Table 1).
MulleinisamemberoftheScrophulariaceae.Thisbotan-
ical family took its name from Scrophularia, or ﬁgwort—a
typical member of the family which was used to treat the
tuberculous infection of the lymph nodes of the neck known
as scrofula [35]. This name was in turn derived from the
Latin scrofa, meaning “breeding sow”. The connection may
be because the glands associated with the disease resemble
the body of a sow or because pigs were thought to be prone
to the disease. The use of the botanical name Scrophularia
can be traced back at least ﬁve hundred years—it was used
by the German botanist Otto Brunfels in 1532 [36], but
the name may have been in use for some time previously.
The 18th century botanists Tournefort (1719) and Linnaeus
(1753) went on to clearly deﬁne the genus, giving ﬁgwort the
oﬃcialbinominaltitleScrophularianodosa[37].Atthattime,Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Appearance and distribution of Great Mullein (Verbascum thapsus). (a) Verbascum thapsus (Great Mullein). Photograph by Zo¨ e
Devlin [4]. (b) For the purpose of botanical distribution records, the British Isles is divided into hectads (10km2 areas). Each dot on the map
indicates that mullein has been identiﬁed in that hectad. As botanical record-keeping is ongoing, hectad distribution maps change over time
[5]. (c) Detailed photograph of dried Mullein leaf. The branched hairs which cover the leaves and help the plant to retain water can clearly
be seen. Photograph by Dr. Jim O’Mahony.
belief in the Doctrine of Signatures was still widespread.
This was the concept that God himself had “signed” plants
which could cure diseases with features of the disease itself or
the organ it aﬀected. In this case, ﬁgwort and related plants
were reputed to cure scrofula because their nodular roots
resembled the diseased lymph nodes [38]. Taking physical
characteristics and medicinal uses into account, Linnaeus
ﬁrst proposed the family Scrophulariaceae (Figure 2).
In a study of the common names of British plants,
Prior states that the word Mullein translated to Moleyn in
Anglo-Saxon and Malen in Old French, derived from the
Latin malandrium—as was the term “malanders”, an old
term for leprosy. He also notes that “the term “malandre”
became also applied to diseases of cattle, to lung diseases
among the rest, and the plant being used as a remedy,
acquired its name of “Mullein” and “Bullock’s Lungwort””
[39]. This links the mullein weed to leprosy and bovine
TB. These conditions—along with scrofula—are now known
to be caused by Mycobacteria. The early herbals also
support a connection with bovine TB—John Parkinson
gave broth of mullein to cattle suﬀering from coughs in
the seventeenth century [40]. Finally, in Cameron’s Gaelic
names of plants, the synonym cow’s lungwort is recorded
while a Gaelic name for mullein is given as Cuingeal—
possibly derived from cuing, meaning “shortness of breath”
[41].
Table 1: Diseases caused by Mycobacteria. Adapted from Palomino
[6].
Name Clinical form
Phthisis/Consumption/White
plague
Former names for Tuberculosis
(TB). Symptoms include
persistent coughing, weight loss,
night sweats, shortness of breath,
and haemoptysis (blood in
sputum)
Scrofula TB of the neck lymph nodes,
known as cervical lymphadenitis
Pott’s disease TB of the spine
Hansen’s disease Leprosy, skin lesions
Bovine TB Tuberculosis in cattle
5.InvestigatingMullein
The extensive historical use of mullein has inspired scientists
to investigate the plant further. To date, a number of the
a n c i e n tc l a i m sh a v ea c t u a l l yp r o v e dt ob et r u e .
Modern day European complimentary medicine fre-
quently hails mullein ﬂower oil as a remedy for earache [42].
Trials have shown a statistically signiﬁcant improvement in
ear pain associated with acute Otitis Media when treated4 Evidence-Based Complementary and Alternative Medicine
Dicotyledons
Subclass: asteridae
Order: scrophulariales
Family: scrophulariaceae
Genus:
Verbascum (including mulleins)
Other genera
including Scrophularia
(ﬁgworts)
Figure 2: Taxonomy of the Scrophulariaceae. Flowering plants
are divided into Monocotyledons and Dicotyledons on the basis
of diﬀerences in their seeds. The Asteridae, a subclass of the
Dicotyledons, contain a large number of medicinal plants. Of
particular interest here is the family Scrophulariaceae, to which the
mulleins (Verbascum spp) belong. (Lines represent other members
at upper levels. Names are omitted for clarity).
with the infusion [43]. The proven anti-inﬂammatory action
of the constituent verbascoside [44] is the likely cause for
this successful treatment though antimicrobial agents may
also play a part. Extracts of the mullein leaf have also
been shown in laboratory studies to possess antitumour,
antiviral,antifungal[45–48],and—mostinterestinglyforthe
purpose of this paper—antibacterial properties. Turker and
Camper showed aqueous Mullein leaf extracts to be eﬀective
against gram positive and gram negative microorganisms,
with the activity against Klebsiella pneumoniae rivalling that
of the Erythromycin control [49]. To date, activity against
Mycobacterium species has not been determined.
6.Battles inNature:VascularPlants
versusMycobacteria
In the absence of an acquired immune system such as that
possessed by humans, plants instead rely on an enormous
variety of small-molecule antimicrobials. Over 100,000 such
compounds are synthesised by plants [57] and activity is
particularly evident against gram positive bacteria [58]. This
is not surprising, as the most common bacteria in soil
1
2
3
4 5
6
7
8
9
10
O
O
O
O O
OH
OH OH
OH
OH
OH
OH
NH
NH
NH
NH
NH
H2N
NH2
(a)
(b)
Figure 3:Plantiridoidsandantibacterialactivity.Iridoidsconsistof
a cyclopentane ring fused to a six-membered oxygen heterocycle—
Figure 3(a). Within plants, they are most often bound to glucose as
glycosides. The injectable drug Streptomycin (Figure 3(b)) which
can be used in the treatment of tuberculosis is glycosidal in
nature. (Figure adapted from IUPAC. McNaught AD, Wilkinson
A. Compendium of Chemical Terminology. Oxford: Blackwell
Scientiﬁc Publications 1997).
come under the genera Bacillus, Clostridium, Corynebac-
terium, and Mycobacterium—all of which are gram positive
rods. Projects in natural product discovery are increasing
following a recent dip [59] and many compounds with
antimycobacterial properties have been uncovered from
natural sources [60, 61]. In 2000, Newton reported that on
a review of literature available at that time, extracts from
138 plant species and 112 pure metabolites had moderate
to high antimycobacterial activities [62]. In the intervening
years, ethnopharmacological studies have continued to add
to the pool of natural antimycobacterials, with promising
compounds extracted from the traditional remedies of
c o u n t r i e sa sf a rr e m o v e da sM e x i c o[ 23], Ethiopia [63], and
India [64]. A 2004 review [60] divided the most promising
botanical compounds tested by in vitro bioassays against
Mycobacterium tuberculosis as follows.
(1) Alkaloids.
(2) Flavones, coumarins, chromone, and chalcone.
(3) Terpenoids.
(4) Steroids and saponins.
(5) Phenols and polyphenols.
Compounds from each of the above classes have also
been isolated from Verbascum species—which includes the
“mulleins”.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Verbascum compounds. A variety of compounds have
been isolated from Verbascum thapsus (“common mullein/great
mullein”) and other members of Verbascum species.
Compound(s) Verbascum species Isolated
from Ref
Triterpenoid saponins,
iridoid glycosides,
steroids, sesquiterpenes,
sterones
V.thapsus Whole plant [50]
Phenylethanoid
glycosides, lignans,
laterioside and
harpagoside
V.thapsus Whole plant [51]
Siakogenins,
oligosaccharides,
ﬂavones
V.thapsus Whole plant [52]
Ajugol, picroside IV,
buddlindeterpene A, B
and C
V.thapsus Whole plant [53]
Flavonoids and
phenylethanoids.
V.densiﬂorum,
V.phlomoides Flowers [54]
Phenylethanoid
glycosides V.wiedemannianum Roots [55]
Verbaspinoside, ajugol,
phenylpropanoid
glycosides
V.spinosum Aerial parts [56]
7.ThePharmacological PotentialofMullein
As already outlined, the mulleins (Verbascum spp.) have
long been known to possess expectorant and demulcent
properties—these are now attributed mainly to its mucilage-
nous constituents and saponins [65]. Although to date
mullein has not been studied in depth against mycobacteria,
antibacterial eﬃcacy against other bacteria has been proven
[49] while extracts of other Verbascum species endemic to
Turkey have activity against the Mycobacterium smegmatis
model [66]. In particular phytochemical investigations have
uncovered a diverse range of compounds within Verbascum
species—both from whole plant [50–53] and speciﬁc parts
[54–56]( Table 2). Lipophilic compounds are particularly
abundant.
As a family, the Scrophulariaceae (to which Verbascum
species belong) harbour the chemotaxonomic markers of
verbascoside, aucubin, and catalpol [67]. The latter are
iridoids—a class of secondary metabolites found in a wide
variety of medicinal plants, most often bound to glucose.
Hydrolysis of the glycosidic bond is thought to be a prereq-
uisite for biological activity [68]. Plants produce iridoids as a
defence against infection by micro-organisms; antimicrobial
action is amongst their wide range of bioactivities. The
compounds shown to be common amongst Verbascum
species are examples of this. The hydrolysis products of
aucubin and catalpol, and aucubin itself, have been shown
to have antimicrobial activity [69, 70]. Verbascoside has
been investigated further. It has been shown to be eﬀective
against a wide range of bacteria [71] but is particularly active
against gram positive bacteria such as Staphylococcus aureus,
including drug resistant strains [72] .O n ep o s s i b l em o d eo f
action is the inhibition of leucine uptake and hence protein
synthesis [73]. Furthermore, Funes et al. have recently
shown that verbascoside can disrupt the phospholipid/water
interface of bacterial membranes [74].
Saponins are also a major chemical constituent of
mullein. This diverse class of compounds are derived from
a 30-carbon precursor and perform a range of biological
actions. While previous studies have shown weak antimi-
crobial activity and often only at low cell density [46, 75],
some of the most promising activities have been against
mycobacteria [76].
8.FuturePotential
It would appear that a member of the Scrophulariaceae
which was once known as “bullock’s lungwort” and has now
been proven to be rich in lipophilic molecules is an ideal
place to mine for potential anti-TB agents. However, while
Verbascum species have been shown to contain a diverse
range of compounds, and similar compounds have been
shown to have antimycobacterial properties, the two have yet
to come together in a comprehensive study. Thorough in-
vitro screening of the bioactivity of mullein extracts against
mycobacteria is required, such as that carried out by Turker
and Camper against other respiratory pathogens. When
dealing with the spectrum of animal- and human-related
mycobacterial diseases, continued laboratory screening of
herbal extracts should be encouraged.
It is clear that many of mullein’s historical uses, syn-
onyms, anecdotes, and local “nick names” connect this plant
with mycobacteria. Of course, the historical links between
mycobacteriaandmulleinmaybecoincidental.Alargenum-
ber of medicinal uses have been recorded for this plant while
its synonyms are almost as numerous. While this is common
for a traditional medicinal plant, numerous connections to
one pathogen—recorded throughout history and across the
world—are not. Whether the link is coincidental or rooted
in true antimycobacterial actions, it merits investigation. An
ancient plant, an ancient infection, an ancient link, and a
modern-day cure?
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